From Consent to Commitment
Patients rarely disengage in a single moment.The warning signs emerge in what they understand, expect, and can sustain.These are the conversations about what turns initial consent into durable participation.
Long-form discussions with the people closest to clinical trial execution: sponsors, CRO leaders, site operators, patient advocates, and behavioral scientists.
Dr. Sarah Chen, VP of Clinical Operations, Major CRO
Site burden is an invisible force in patient dropout. This conversation examines how coordinator fatigue, delayed procedures, and cascading protocol friction drive disengagement before withdrawal becomes visible.
Listen to the EpisodeConversations about the conditions that determine whether participation holds.
Maria Santos, Patient Advocacy Lead
Why caregiver readiness can determine whether pediatric and caregiver-dependent participation remains viable.
Dr. James Liu, Chief Medical Officer
The difference between patients who interact with trial content and patients who are prepared to sustain participation.
Dr. Rebecca Torres, Head of Patient Experience
What happens to understanding when the protocol changes, and why re-consent alone rarely restores readiness.
Each episode moves beyond engagement metrics to examine the human and operational conditions underneath them.
How commitment erodes before withdrawal appears in the data.
How site burden, staffing, and protocol logistics affect patient readiness.
The distance between informed consent and understood commitment.
How decisions, routines, and social dynamics shape participation.
No single function owns the entire patient journey. The conversation must include the people who see different points of failure.
Subscribe for discussions that challenge how the industry thinks about participation, retention, and completion.
It is a long-form conversation series exploring what separates initial clinical trial consent from sustained participation and completion.
The series features CRO leaders, site operators, pharmaceutical sponsors, patient advocates, behavioral scientists, and other experts closest to trial execution.
Topics include patient readiness, caregiver participation, site burden, protocol comprehension, behavioral science, retention risk, and the operational conditions that influence completion.
Yes. Use the guest and topic suggestion form.
In two days, you get three execution diagnostics on your program.
How likely each eligible patient cluster is to activate, persist, and complete, before any intervention.
The barriers most likely to suppress activation, enrollment, and completion in each cluster, and how to mitigate them.
Which clusters to target, which barriers to address, which interventions to deploy, and what completion lift to expect.